Ceftolozane/Tazobactam and Ceftazidime/Avibactam: An Italian Multi-center Retrospective Analysis of Safety and Efficacy in Children With Hematologic Malignancies and Multi-drug Resistant Gram-negative Bacteria Infections

Pediatr Infect Dis J. 2022 Dec 1;41(12):994-996. doi: 10.1097/INF.0000000000003716. Epub 2022 Sep 16.
No abstract available

Publication types

  • Multicenter Study

MeSH terms

  • Anti-Bacterial Agents* / adverse effects
  • Ceftazidime / pharmacology
  • Ceftazidime / therapeutic use
  • Cephalosporins / therapeutic use
  • Child
  • Drug Combinations
  • Drug Resistance, Multiple, Bacterial*
  • Gram-Negative Bacteria
  • Hematologic Neoplasms* / complications
  • Hematologic Neoplasms* / drug therapy
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / drug therapy
  • Pseudomonas aeruginosa
  • Retrospective Studies
  • Tazobactam / therapeutic use

Substances

  • Anti-Bacterial Agents
  • avibactam
  • Ceftazidime
  • ceftolozane
  • ceftolozane, tazobactam drug combination
  • Cephalosporins
  • Drug Combinations
  • Tazobactam